Narlumosbartmab plus chemo for bone cancers with giant cells
Part of Bones, joints & muscles, Cancer clinical trials.
This trial tests a new drug called Narlumosbartmab added to standard chemotherapy for certain types of bone cancer that have eaten away at the bone and contain large, abnormal cells. It is for people who have not yet started standard treatment and whose tumors can be removed with surgery.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are at least 8 years old.
- You have a specific type of bone cancer (high-grade osteosarcoma, Ewing sarcoma, malignant giant cell tumor, or undifferentiated pleomorphic sarcoma) that has been confirmed by biopsy and includes multinucleated giant cells.
- You have not yet received standard treatment for this cancer, and you plan to have surgery at the study center.
- You are in good enough health to walk and care for yourself (ECOG score 0 or 1), and your doctor expects you to live more than 6 months.
- Your blood counts, liver, and kidney function are within acceptable ranges as shown on recent blood tests.
- You have no active jaw or dental problems, and you are not taking or planning to take certain bone medications or other cancer treatments during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 3 study tests narlumosbart (JMT103) to see if it works and is safe for people with giant cell tumor of bone that cannot be fully removed with surgery. If you qualify, you may be compared against another treatment and monitored closely for side effects and tumor response.
This trial tests adding a new drug (narlumosbart) and targeted radiation to standard chemotherapy and immunotherapy for people with advanced non-small cell lung cancer that has spread to the bones. The goal is to see if this combination works better than standard treatment alone.
This study tests a combination of chemo medicines (gemcitabine, doxorubicin, docetaxel) plus an immunotherapy drug (nivolumab) for advanced sarcoma that can’t be removed with surgery. It may help shrink tumors and slow disease growth in people whose cancer has already been treated and is measurable on scans.
This trial is testing a new drug called narlumosbart (a type of targeted biologic medicine) compared to denosumab (a standard bone-strengthening treatment) for people with multiple myeloma that has caused bone damage. The goal is to see which drug better protects bones and reduces complications.
This trial tests a new drug, nelmastobart, combined with the chemotherapy docetaxel, for people with advanced non-small cell lung cancer that has a high level of a protein called BTN1A1. It is for patients who have already tried other treatments and are looking for a new option.
This trial tests whether adding immunotherapy (a treatment that helps your immune system fight cancer) to chemotherapy can help young people whose bone or soft tissue sarcoma has come back or hasn't responded to previous treatment.
Hear when a new Malignant Bone Tumor trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.